Conference Coverage

Edaravone slows progression of ALS when started early on

Key clinical point: When added to standard of care, edaravone slows loss of function in patients with early-stage ALS.

Major finding: Compared with placebo, edaravone was associated with a smaller 24-week reduction in scores on the Amyotrophic Lateral Sclerosis Functional Rating Scale–Revised (–5.01 vs. –7.50).

Data source: A randomized phase III trial among 137 patients with definite or probable ALS, normal respiratory function, and ability to perform most activities of daily living.

Disclosures: Dr. Palumbo disclosed that he is an employee of Mitsubishi Tanabe Pharma Development America the maker of edaravone. The studies were sponsored by Mitsubishi Tanabe Pharma Corporation.


 

AT THE AAN 2016 ANNUAL MEETING

References

Rounding out the set of trials was a small randomized placebo-controlled trial among 25 patients with more advanced ALS, done at the request of Japanese health authorities. Results showed that edaravone was safe in this population but had no clear benefit.

Dr. Palumbo disclosed that he is an employee of Mitsubishi Tanabe Pharma Development America, Inc. The trials were sponsored by Mitsubishi Tanabe Pharma Corporation.

Next Article: